



Original Article

Evaluating the Effectiveness of AI Chatbots in Chronic Disease Self-Management

Srinivasa Kalyan Vangibhurathachhi
Solution Architect, Texas, USA.

Abstract - This analysis examines the effectiveness of AI-powered chatbots in chronic disease self-management, focusing on conditions such as diabetes, cardiovascular diseases, respiratory disorders, and mental health comorbidities. Chatbots facilitate adherence to the treatment, monitoring of the result, and educating patients, through the possibilities of real-time interaction, automated monitoring as well as personal coaching. Cases show the increment of clinical outcomes such as HbA1c and blood pressure as well as a decline in the dependency on emergency care. Nevertheless, despite their scalability and cost-efficiency, some critical issues are still outstanding, including the privacy of data, predictive bias, regulatory limitations, and the issue of user trust. Future research needs and their implications on the long-term efficacy of the applicability to populations are also described in the paper. The results indicate that under the conditions of ethical design and appropriate control, AI chatbots can also be a radical force in building chronic care ecosystems that are accessible, continuous, and responsive.

Keywords - AI Chatbots, Chronic Disease Self-Management, Digital Health Interventions, Patient Engagement, Health Technology Evaluation.

1. Introduction

The growing prevalence of global chronic diseases such as diabetes, cardiovascular disorders and respiratory conditions has placed unprecedented pressure on healthcare systems worldwide (Al Meslamani, 2024). These chronic diseases are characterized by long-term care and require ongoing medical attention, lifestyle modifications and patient engagement in daily self-care routines. Traditional healthcare models which are reliant on episodic clinical encounters tend to fail in providing continuous support required for effective chronic disease management (Ladds et al., 2023). This has necessitated the integration of scalable digital health solutions. Artificial intelligence (AI)-powered chatbots have emerged as potential tools to address these systemic gaps (Kurniawan et al., 2024). Leveraging natural language processing (NLP) and machine learning, these systems deliver interactive, context-aware communication that can replicate certain aspects of human support (Feng et al., 2025). Their deployment in health contexts includes functionalities such as symptom monitoring, medication reminders, and behavioral coaching, enabling real-time interaction without requiring continuous clinician involvement (Kalusivalingam et al., 2021). As such, AI chatbots present a disruptive opportunity to redefine chronic disease self-management.

The following specific research objectives guide the course of the research process:

- Evaluate how effective AI chatbots are in supporting chronic disease self-management
- Analyze usability, engagement, clinical outcomes, and patient satisfaction
- Identify current limitations and areas for future development

2. Problem Statement

Chronic disease management involves a lot of behavioral discipline, systematic observation, and strict medical compliance with treatment. However, such brittle engagement with patients is usually affected by healthcare discontinuity, mental overload, and mental exhaustion (Jerjes et al., 2025). Access to healthcare among low-resource settings is further restricted by geographic and financial obstacles (Lamichhane & Neupane, 2022), as well as poor health literacy that interferes with self-management (Magi et al., 2024). The traditional methods like leaflets, phone-based follow-ups, and face-to-face counseling are also non-adjustable and do not provide real-time feedback (Sherlaw-Johnson et al., 2024). Tracking tools based on manual input, such as paper diaries or simple applications, have low engagement because they lack usability and personalization (Balaskas et al., 2021). They lack scalability because such approaches rely extensively on human participation (Mair et al., 2023). Conversely, chatbots powered by AI would be a sustained, dynamic, and cost-efficient proposal, which would maintain a human-like interaction simulation, automatic monitoring, and personal interventions according to the contexts (Uzoka et al., 2024; Anisha et al., 2024).

3. Proposed Solution: AI Chatbots for Chronic Care

3.1. What are AI chatbots and Key Functionalities

The medical AI chatbots are a system that is incorporated into natural language processing, machine learning, and frequently linked to cloud technology infrastructures or mobile platforms (Kalusivalingam et al., 2021). They are able to engage with patients through text or voice and provide health-related feedback, behavioral prompts, and tracking of data. Chronic care AI chatbots have to offer a diverse selection of functions in order to be clinically useful and functionally efficient (Kurniawan et al., 2024). Typical capabilities are those of symptom checkers, in which the patients triage and understand sensations in their bodies, often by being presented with a rule-based algorithm or trained classifier (You et al., 2023). In addition, medication reminders are essential and highly required by polypharmacy patients since they help to avoid skipping doses and timing issues (Ogbuagu et al., 2023). Personalized healthcare recommendations can also be provided by Chatbots, which will scale recommendations according to previous patient entries, type of disease, and behavior (Aggarwal et al., 2023). Integration of educational messages in forms that are digestible and conversational is another major functionality. Chatbots can dedicate time to the provision of context-specific education, unlike lengthy articles or pamphlets, which may overwhelm patients (Laymouna et al., 2024). Alongside sentiment analysis abilities, which NLP facilitates, chatbots can be even more useful as they can identify emotional phrasing in user messages (Bilquise et al., 2022). This enables system escalation of cases that can result in psychological distress or behavioral risk to human providers. Critical symptoms or advancing conditions can be set as alerts that activate an automated triage practice or medical alert, consequently minimizing the time delay of care escalation and resulting in a safety outcome (Blythe et al., 2022). The flowchart below is a diagram of the principal elements in an AI medical chatbot, which starts with the input of the user that is analyzed through natural language processing (NLP). The system also channels the input to various modules that include symptom checking, medicine reminders, and education delivery that give context-specific feedback or escalation where needed.




Figure 1. Functional Architecture of an AI Chatbot for Chronic Disease Self-Management (Kataoka et al., 2021)

3.2. Advantages for Chronic Disease Patients

The use of AI chatbots in chronic care creates a paradigm shift due to a continuously available, non-invasive, and scalable connection with patients (Zidaru et al., 2021). They do not have time restrictions, which eliminates boundaries against care because they are available around the clock. Patients can go to them at the time they think it would help them in need when symptoms arise or when they are unsure of what is happening (Branda et al., 2025). This ever-present nature has been indicated to enhance compliance with the treatment regimens by providing contextual feedback and giving real-time feedback. In comparison with static health education tools, chatbots can be based on dynamic personalization, changing the responses to inquiries based on user entry, behavioral background, and disease progression. This increases user retention and compliance (Ittarat et al., 2023). Moreover, chatbots decrease the necessity to continuously visit the doctor when it comes to routine monitoring activities (Aggarwal et al., 2023). They support remote data gathering due to structured conversational interfaces that collect measures of interest such as blood glucose level, blood pressure, or medication use, which may either be stored or shared with care providers (Gallo et al., 2023). This digital connectedness between care reduces disruption in the case of a patient with mobility issues or patients in rural areas, and is empowering in terms of active self-management (Tanniru, 2019). Furthermore, routine interactions can be automated, thus streamlining the workload of clinicians who would be able to pay attention to complicated or emergent situations, making the health care delivery system more efficient (Alowais et al., 2023).

4. Use Cases and Real-World Applications

4.1. Diabetes Management

The most common AI and chatbot applications in diabetes management are helping glycemic control by means of personalized real-time communication (Jahangir et al., 2023). Some systems, such as Lark Health, provide diet tracking, medication reminders, and behaviour coaching via conversational AI (Loughnane et al., 2025). Ada Health is an application that deploys structured symptom-checking algorithms that can give users decision trees to follow and indicate the right course of action (ADA, 2024). These chatbots enable connection to glucometers or manual entry to identify glucose level trends. Embedded behavioral models use the cognitive-behavioral strategy to increase self-efficacy and promote long-term participation (Aggarwal et al., 2023). According to the results of clinical studies towards the end of 2024 and in 2025, the prolonged use of chatbots can help lower HbA1c levels in patients with type 2 diabetes by a significant margin (Abusamaan et al., 2024; Loughnane et al., 2025). Figure 2 demonstrates an example of a chatbot interface, where glucose monitoring, individual coaching, and educational activities on symptoms are integrated, which enables real-time feedback and enhanced adherence to diabetes management guidelines by patients.




Figure 2. Interface of an AI Chatbot for Diabetes Self-Management (Lark Health, 2025)

Additionally, the utilization of chatbots is associated with an increase in rates of adherence to the exercise and diet protocols, as the constant reinforcement effect is supported and traditional care models are unable to maintain such rates because of the inconsistency of the contacts (Chew, 2022). Besides the provider burden, these tools allow the flagging of unusual symptom reporting or blood sugar trends so that the clinical staff can review them at an early stage.

4.2. Hypertension or Cardiovascular Care

Cardiovascular health AI chatbots help users to monitor the key indicators of this state, like systolic and diastolic pressure, connecting them to the intake of medications and life habits (Chen et al., 2024). The systems are compatible with networked monitors and mobile devices to obtain and analyze readings closer to real-time (Chen et al., 2024). They stimulate the use of antihypertensive medicines and suggest behavioral interventions such as sodium-restriction, physical activity, and stress-management through the evidence-based protocols (Aggarwal et al., 2023). Chatbots can elevate cases to physicians or encourage abusers to check compliance when deviations are observed. Moreover, the possibility of integration with wearables allows detecting inconsistencies in heart rate variability or activity, issuing warning notifications regarding the cardiovascular risk (Sultana et al., 2025). This is the feedback loop that facilitates dynamic coaching. Research indicates that these interventions lower blood pressure during ambulation and enhance the persistence of medication, particularly when applied in patients with a low level of medication compliance (Babel et al., 2021).

4.3. Respiratory Diseases

The use of AI chatbots becomes increasingly common in the context of asthma and COPD management because both diseases can be characterized by the unstable progression of symptoms and environmental factors. They encourage users to report symptoms such as wheezing or cough, which allows the identification of patterns in respiratory deterioration (Kurniawan et al., 2024). With chatbots, the patient also receives reminders of medications and inhalers to follow the health plans, and also provides guidance as to what to do next depending on the severity of symptoms (Cook et al., 2024). Integration with environmental data sources, such as air quality indices or pollen levels, helps users proactively avoid triggers (Miller et al., 2025). Triage algorithms also evaluate patterns of symptoms and increase care where necessary (Tahernejad et al., 2024). Chatbots will alleviate the workload of clinicians through automating regular surveillance, further contributing to early

intervention. According to the study of Vaismoradi et al. (2024), a reduction in unscheduled healthcare utilization prompted by such tools resulted in timely self-care or medical attention.

4.4. Mental Health Integration

Mental health problems, including anxiety and depression, are common in those living with chronic physical illness, and in addition to increasing the burden of disease, they diminish adherence to therapy (Berk et al., 2023). As Omarov et al. (2023) note, the purpose of AI chatbots that incorporate mental health support is to bridge such a divide because cognitive-behavioral interventions are provided via dialogue forms of interface. Those scholars also offer that these systems are able to identify mood patterns, present psychoeducational messages, and suggest coping methods in real time.

Chatbots like Woebot and Wysa have been proven to be effective in causing a positive shift in the mood and lowering perceived stress levels of those who use them by implementing systematic psychological loops (Farzan et al., 2025). Such mental health features can be incorporated into chronic disease management platforms to increase the sense of overall engagement and decrease the level of care fragmentation (Joo, 2023). Addressing both emotional trouble and somatic symptoms, chatbots will help implement holistic care, hence avoiding the progression of preventable diseases in cases of neglect and refusal to comply. Table 1 below provides comparative overview of ai chatbot applications in chronic disease management.

Table 1. Comparative Overview of AI Chatbot Applications in Chronic Disease Management

Disease Area	Key Chatbot Functions	Integration Features	Reported Outcomes
Diabetes	Personalized coaching, diet tracking, symptom logging, and medication reminders	Glucometer syncing, lifestyle data input, and behavior change modules	Reduced HbA1c levels, improved adherence to diet/exercise
Cardiovascular	BP tracking, medication scheduling, stress management, lifestyle recommendations	Integration with BP monitors and mobile health apps	Lowered systolic/diastolic BP, improved medication adherence
Respiratory (Asthma/COPD)	Symptom monitoring (wheezing, coughing), inhaler reminders, trigger alerts	Air quality data integration, action plan guidance	Fewer exacerbations, reduced unscheduled care visits
Mental Health	Mood tracking, CBT-based prompts, psychoeducation, stress relief techniques	Integrated with chronic care platforms, chatbot-based cognitive therapy	Reduced anxiety/depression scores, increased user engagement

5. Impact Analysis and Effectiveness Metrics

5.1. Evaluation Metrics

The outcomes of the AI chatbots in the condition of chronic disease self-management are measured with quantitative and qualitative measurements. The behavioral outcomes of usage frequency, response rate to messages, and duration are the measures of user engagement and the continued interaction and could be associated with better health literacy and behavioral adherence (Aggarwal et al., 2023). At a clinical level, the useful measures include the improvement of blood sugar (HbA1c), blood pressure, the severity of symptoms, and the percentage of those who take the medication, as these are objective signs of an impact (Billoro et al., 2022). Indicatively, an AI-based tool was found to decrease systolic blood pressure by 5-10 millimeters of mercury (mmHg) and HbA1c up to 1.1 percent in patients with type 2 diabetes over 3-6 months (Shobako et al., 2022). Chatbots are also effective because of patient-reported outcomes like ease of use, perceived usefulness, and satisfaction. The high level of satisfaction is associated with a better level of adherence and less use of emergency services (Eaton et al., 2024). There are fewer needless hospital admissions, which are common occurrences in cases of early diagnoses and preemptive measures. Furthermore, AI produces self-monitoring analytics consisting of closed-loop feedback, which will allow clinicians to estimate and screen high-risk users and customize care (Esmaeilzadeh et al., 2025). However, contextual factors such as digital literacy, language access, and integration of the health system demonstrate high impact on the general efficacy of the populations. Differences between major healthcare delivery indicators of traditional care models and AI chatbot-based interventions are represented in Table 2 below. The AI chatbots have shown a greater level of compliance, interactive learning, medium pricing, and higher scalability, which makes them prime candidates to become a good option for enhancing chronic disease self-management.


Table 2. Comparative Evaluation of Traditional Care vs. AI Chatbot Support in Chronic Disease Management

Metric	Traditional Care	AI Chatbot Support
Adherence	Moderate	High
Education	Passive	Interactive
Cost	High	Moderate
Scalability	Limited	High

6. Challenges and Future Research Directions

6.1. Challenges

While AI chatbots show promise in chronic disease management, widespread adoption faces key challenges. Data privacy is a major concern, especially when chatbots operate outside HIPAA or GDPR protections (Marks & Haupt, 2023), raising risks of breaches and weak consent processes (Khan et al., 2024). Algorithmic bias is another issue many systems are trained on non-representative datasets, resulting in culturally inappropriate or inaccurate advice (Algumaei et al., 2025). Without clinical oversight, chatbot-generated recommendations may be unreliable or harmful. Regulatory uncertainty further hinders deployment, with most regions lacking clear certification standards. Poor usability such as clunky interfaces or limited language support also erodes trust and engagement (Jin et al., 2025). Ethical design and consistent performance across diverse users are essential for responsible integration.

**Figure 3. Challenges for implementation of AI chatbots (Adapted from Radanliev, 2025)**

6.2. Research Directions

In the future, more longitudinal studies ought to be considered to determine the long-term clinical efficacy of chatbot applications after a few months or years. The existing evidence is mainly short-term, which makes it difficult to define the long-term adherence and the rates of complications, as well as the cost-effectiveness of the method. There exists as well a necessity to analyze the work of chatbots in different demographic categories, such as age, socioeconomic status, literacy level, and cultural background, to overcome disparities in the accessibility of digital health (Moore et al., 2025). Firm processes of confirmation are needed: verifying the efficacy of chatbot-guided care outcomes against other conventional measures will contribute to their clinically reasonable status and secure the limits of administration (Branda et al., 2025). Simultaneously, interdisciplinary research must aim at inventing adaptive algorithms that can learn from the patient responses, behavioural information, and shifting clinical options. Such improvements would make the foregoing both personal and clinically rigorous in a field setting.

7. Conclusion

The use of AI chatbots to assist people with chronic conditions is ground-breaking since it addresses existing gaps in the current approach to care. They facilitate adherence to treatment, symptom monitoring, and teaching patients in real time and in a personal way. Studies indicate a better result in blood glucose levels and blood pressure levels, and a decline in healthcare utilization. Nonetheless, adoption among large populations will require the issues of data security, clinical accuracy, algorithmic bias, and user trust to be properly resolved. Their performance is not very high without stringent regulation frameworks and clinical verification. In future studies, long-term efficacy between different populations must be measured and should be suited in terms of compliance with medical standards as well as usability. Chatbots, when used in a responsible fashion, will help transform chronic care into a responsive and accessible model.

References

- [1] A. A. Moore, J. R. Ellis, N. Dellavalle, M. Akerson, M. Andazola, E. G. Campbell, and M. DeCamp, "Patient-facing chatbots: Enhancing healthcare accessibility while navigating digital literacy challenges and isolation risks—a mixed-methods study," *Digital Health*, vol. 11, 2025, doi: 10.1177/20552076251337321.
- [2] A. Aggarwal, C. C. Tam, D. Wu, X. Li, and S. Qiao, "Artificial intelligence-based chatbots for promoting health behavioral changes: systematic review," *J. Med. Internet Res.*, vol. 25, pp. 1-17, 2023, doi: 10.2196/40789.
- [3] A. Algumaei, N. M. Yaacob, M. Doheir, M. N. Al-Andoli, and M. Algumaei, "Symmetric therapeutic frameworks and ethical dimensions in AI-based mental health chatbots (2020–2025): a systematic review of design patterns, cultural balance, and structural symmetry," *Symmetry*, vol. 17, no. 7, 2025, doi: 10.3390/sym17071082.
- [4] A. Babel, R. Taneja, F. Mondello Malvestiti, A. Monaco, and S. Donde, "Artificial intelligence solutions to increase medication adherence in patients with non-communicable diseases," *Front. Digit. Health*, vol. 3, p. 669869, 2021, doi: 10.3389/fdgth.2021.669869.
- [5] A. Balaskas, S. M. Schueller, A. L. Cox, and G. Doherty, "The functionality of mobile apps for anxiety: systematic search and analysis of engagement and tailoring features," *JMIR Mhealth Uhealth*, vol. 9, no. 10, pp. 1-18, 2021, doi: 10.2196/26712.
- [6] A. K. Kalusivalingam, A. Sharma, N. Patel, and V. Singh, "Enhancing patient care through IoT-enabled remote monitoring and AI-driven virtual health assistants: implementing machine learning algorithms and natural language processing," *Int. J. AI Machine Learn.*, vol. 2, no. 3, pp. 1-24, 2021. [Online]. Available: <https://www.cognitivecomputingjournal.com/index.php/IJAIML-V1/article/view/75>.
- [7] A. Tahernejad, A. Sahebi, A. S. S. Abadi, and M. Safari, "Application of artificial intelligence in triage in emergencies and disasters: a systematic review," *BMC Public Health*, vol. 24, no. 1, p. 3203, 2024, doi: 10.1186/s12889-024-20447-3.
- [8] A. Uzoka, E. Cadet, and P. U. Ojukwu, "Leveraging AI-powered chatbots to enhance customer service efficiency and future opportunities in automated support," *Comput. Sci. IT Res. J.*, vol. 5, no. 10, pp. 2485-2510, 2024, doi: 10.51594/csitrj.v5i10.1676.
- [9] A. Z. Al Meslamani, "Strategies for reducing chronic disease burden during pandemics," *Curr. Med. Res. Opin.*, vol. 40, no. 2, pp. 193-197, 2024, doi: 10.1080/03007995.2023.2295410.
- [10] ADA, "Ada: Your health companion," Ada, 2024. [Online]. Available: <https://ada.com/>. [Accessed: Jul. 12, 2025].
- [11] B. B. Billoro, A. M. Abdi, W. A. Abero, A. B. Fite, and B. Basgut, "A preliminary study to evaluate the impact of pharmaceutical care services on clinical outcome and medication adherence in type 2 diabetes mellitus patients from Ethiopian perspective," *Afr. Health Sci.*, vol. 22, no. 4, pp. 104-118, 2022, doi: 10.4314/ahs.v22i4.14.
- [12] B. Lamichhane and N. Neupane, "Improved healthcare access in low-resource regions: a review of technological solutions, 1021," 2022. [Online]. Available: <https://doi.org/10.48550/arXiv.2205.10913>.
- [13] B. Omarov, Z. Zhumanov, A. Gumar, and L. Kuntunova, "Artificial intelligence enabled mobile chatbot psychologist using AIML and cognitive behavioral therapy," *Int. J. Adv. Comput. Sci. Appl.*, vol. 14, no. 6, pp. 137-146, 2023.
- [14] C. E. Magi, S. Bambi, L. Rasero, Y. Longobucco, K. El Aoufy, C. Amato, ... and P. Iovino, "Health literacy and self-care in patients with chronic illness: a systematic review and meta-analysis protocol," *Healthcare*, vol. 12, no. 7, pp. 1-10, Mar. 2024, doi: 10.3390/healthcare12070762.
- [15] C. Eaton, N. Vallejo, X. McDonald, J. Wu, R. Rodríguez, N. Muthusamy, ... and K. A. Rieckert, "User engagement with mHealth interventions to promote treatment adherence and self-management in people with chronic health conditions: systematic review," *J. Med. Internet Res.*, vol. 26, 2024, doi: 10.2196/50508.
- [16] C. Loughnane, J. Laiti, R. O'Donovan, and P. J. Dunne, "Systematic review exploring human, AI, and hybrid health coaching in digital health interventions: trends, engagement, and lifestyle outcomes," *Front. Digit. Health*, vol. 7, p. 1536416, 2025, doi: 10.3389/fdgth.2025.1536416.
- [17] C. Sherlaw-Johnson, T. Georghiou, S. Reed, R. Hutchings, J. Appleby, S. Bagri, ... and A. Ramsay, "Investigating innovations in outpatient services: a mixed-methods rapid evaluation," *Health Social Care Delivery Res.*, vol. 12, no. 38, pp. 1-162, 2024, doi: 10.3310/VGQD4611.
- [18] D. Cook, D. Peters, L. Moradbakhti, T. Su, M. Da Re, B. W. Schuller, ... and R. A. Calvo, "A text-based conversational agent for asthma support: mixed-methods feasibility study," *Digit. Health*, vol. 10, 2024, doi: 10.1177/20552076241258276.
- [19] E. Ladds, T. Greenhalgh, R. Byng, S. Rybczynska-Bunt, A. Kalin, and S. Shaw, "A contemporary ontology of continuity in general practice: capturing its multiple essences in a digital age," *Soc. Sci. Med.*, vol. 332, 2023, doi: 10.1016/j.socscimed.2023.116112.
- [20] F. Branda, M. Stella, C. Ceccarelli, F. Cabitza, G. Ceccarelli, A. Maruotti, ... and F. Scarpa, "The role of AI-based chatbots in public health emergencies: a narrative review," *Future Internet*, vol. 17, no. 4, p. 145, 2025, doi: 10.3390/fi17040145.
- [21] G. Bilquise, S. Ibrahim, and K. Shaalan, "Emotionally intelligent chatbots: A systematic literature review," *Hum. Behav. Emerg. Technol.*, 2022, doi: 10.1155/2022/9601630.
- [22] G. Feng, F. Weng, W. Lu, L. Xu, W. Zhu, M. Tan, and P. Weng, "Artificial intelligence in chronic disease management for aging populations: a systematic review of machine learning and NLP applications," *Int. J. Gen. Med.*, pp. 3105-3115, 2025, doi: 10.2147/IJGM.S516247.

- [23] H. S. J. Chew, "The use of artificial intelligence-based conversational agents (chatbots) for weight loss: scoping review and practical recommendations," *JMIR Med. Inform.*, vol. 10, no. 4, e32578, 2022, doi: 10.2196/32578.
- [24] J. L. Mair, O. Castro, A. Salamanca-Sanabria, B. F. Frese, F. Von Wangenheim, E. S. Tai, ... and F. Müller-Riemenschneider, "Exploring the potential of mobile health interventions to address behavioural risk factors for the prevention of non-communicable diseases in Asian populations: a qualitative study," *BMC Public Health*, vol. 23, no. 1, p. 753, 2023, doi: 10.1186/s12889-023-15598-8.
- [25] J. Y. Joo, "Fragmented care and chronic illness patient outcomes: a systematic review," *Nurs. Open*, vol. 10, no. 6, pp. 3460-3473, 2023, doi: 10.1002/nop2.1607.
- [26] Lark Health, "Diabetes care," 2025. [Online]. Available: <https://www.lark.com/diabetes>. [Accessed: Jul. 12, 2025].
- [27] M. Berk, O. Köhler-Forsberg, M. Turner, B. W. Penninx, A. Wrobel, J. Firth, ... and W. Marx, "Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management," *World Psychiatry*, vol. 22, no. 3, pp. 366-387, 2023, doi: 10.1002/wps.21110.
- [28] M. Farzan, H. Ebrahimi, M. Pourali, and F. Sabeti, "Artificial intelligence-powered cognitive behavioral therapy chatbots, a systematic review," *Iranian J. Psychiatry*, vol. 20, no. 1, p. 102, 2025, doi: 10.18502/ijps.v20i1.17395.
- [29] M. H. Kurniawan, H. Handiyani, T. Nuraini, R. T. S. Hariyati, and S. Sutrisno, "A systematic review of artificial intelligence-powered (AI-powered) chatbot intervention for managing chronic illness," *Ann. Med.*, vol. 56, no. 1, pp. 1-14, 2024, doi: 10.1080/07853890.2024.2302980.
- [30] M. Ittarat, W. Cheungpasitporn, and S. Chansangpetch, "Personalized care in eye health: Exploring opportunities, challenges, and the road ahead for chatbots," *J. Pers. Med.*, vol. 13, no. 12, p. 1679, 2023, doi: 10.3390/jpm13121679.
- [31] M. Laymouna, Y. Ma, D. Lessard, T. Schuster, K. Engler, and B. Lebouché, "Roles, users, benefits, and limitations of chatbots in health care: rapid review," *J. Med. Internet Res.*, vol. 26, e56930, 2024, doi: 10.2196/56930.
- [32] M. M. Khan, N. Shah, N. Shaikh, A. Thabet, and S. Belkhair, "Towards secure and trusted AI in healthcare: a systematic review of emerging innovations and ethical challenges," *Int. J. Med. Inform.*, 2024, doi: 10.1016/j.ijmedinf.2024.105780.
- [33] M. Marks and C. E. Haupt, "AI chatbots, health privacy, and challenges to HIPAA compliance," *JAMA*, vol. 330, no. 4, pp. 309-310, 2023, doi: 10.1001/jama.2023.9458.
- [34] M. S. Abusamaan, J. Ballreich, A. Dobs, B. Kane, N. Maruthur, J. McGready, ... and N. N. Mathioudakis, "Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial," *Trials*, vol. 25, no. 1, p. 325, 2024, doi: 10.1186/s13063-024-08177-8.
- [35] M. Tanniru, "Engagement leading to empowerment—digital innovation strategies for patient care continuity," *J. Hosp. Manag. Health Policy*, vol. 3, 2019, doi: 10.21037/jhmhp.2019.09.01.
- [36] M. Vaismoradi, J. Rae, H. Turunen, and P. A. Logan, "Specialized nurses' role in ensuring patient safety within the context of telehealth in home care: A scoping review," *Digital Health*, vol. 10, 2024, doi: 10.1177/20552076241287272.
- [37] N. Shobako, C. Goto, T. Nakagawa, T. Yamato, S. Kondo, F. Nakamura, ... and K. Honda, "Hypotensive and HbA1c reducing effect of novel dietary intervention program 'COMB meal program': Two randomized clinical trials," *J. Funct. Foods*, vol. 98, p. 105279, 2022.
- [38] O. O. Ogbuagu, A. O. Mbata, O. D. Balogun, O. Oladapo, O. O. Ojo, and M. Muonde, "Artificial intelligence in clinical pharmacy: Enhancing drug safety, adherence, and patient-centered care," *Int. J. Multidisciplinary Res. Growth Eval.*, vol. 4, no. 1, pp. 814-822, 2023, doi: 10.54660/IJMRGE.2023.4.1-814-822.
- [39] P. Esmailzadeh, M. Maddah, and T. Mirzaei, "Using AI chatbots (e.g., CHATGPT) in seeking health-related information online: The case of a common ailment," *Comput. Hum. Behav. Artif. Humans*, vol. 3, pp. 1-16, 2025, doi: 10.1016/j.chbah.2025.100127.
- [40] P. Radanliev, "Privacy, ethics, transparency, and accountability in AI systems for wearable devices," *Front. Digital Health*, vol. 7, p. 1431246, 2025, doi: 10.3389/fdgth.2025.1431246.
- [41] R. Blythe, R. Parsons, N. M. White, D. Cook, and S. McPhail, "A scoping review of real-time automated clinical deterioration alerts and evidence of impacts on hospitalised patient outcomes," *BMJ Qual. Saf.*, vol. 31, no. 10, pp. 725-734, 2022, doi: 10.1136/bmjqs-2021-014527.
- [42] S. A. Alowais, S. S. Alghamdi, N. Alsuhebany, T. Alqahtani, A. I. Alshaya, S. N. Almohareb, ... and A. M. Albekairy, "Revolutionizing healthcare: the role of artificial intelligence in clinical practice," *BMC Med. Educ.*, vol. 23, no. 1, p. 689, 2023, doi: 10.1186/s12909-023-04698-z.
- [43] S. A. Anisha, A. Sen, and C. Bain, "Evaluating the potential and pitfalls of AI-powered conversational agents as humanlike virtual health carers in the remote management of noncommunicable diseases: scoping review," *J. Med. Internet Res.*, vol. 26, pp. 1-47, 2024, doi: 10.2196/56114.
- [44] S. Gallo, F. Paterno, and A. Malizia, "Conversational interfaces in IoT ecosystems: where we are, what is still missing," in *Proc. 22nd Int. Conf. Mobile Ubiquitous Multimedia*, Dec. 2023, pp. 279-293, doi: 10.1145/3626705.3627775.
- [45] S. Jin, B. Kim, and K. Han, "I don't know why I should use this app: holistic analysis on user engagement challenges in mobile mental health," in *Proc. 2025 CHI Conf. Human Factors Comput. Syst.*, Apr. 2025, pp. 1-23, doi: 10.1145/3706598.3713732.
- [46] S. Sultana, M. S. H. Hriday, R. Haque, and M. Das, "Health monitoring through wearables: A systematic review of innovations in cardiovascular disease detection and prevention," *Strategic Data Manage. Innov.*, vol. 2, no. 1, pp. 96-115, 2025, doi: 10.71292/sdmi.v2i01.13.

- [47] T. Miller, I. Durlik, E. Kostecka, P. Kozlovska, A. Łobodzińska, S. Sokołowska, and A. Nowy, "Integrating artificial intelligence agents with the internet of things for enhanced environmental monitoring: applications in water quality and climate data," *Electronics*, vol. 14, no. 4, p. 696, 2025, doi: 10.3390/electronics14040696.
- [48] T. Zidaru, E. M. Morrow, and R. Stockley, "Ensuring patient and public involvement in the transition to AI-assisted mental health care: A systematic scoping review and agenda for design justice," *Health Expect.*, vol. 24, no. 4, pp. 1072-1124, 2021, doi: 10.1111/hex.13299.
- [49] W. Jerjes, D. Harding, and A. Hilton, "Addressing treatment fatigue, therapeutic inertia, and cognitive dissonance in musculoskeletal pain management in primary care setting," *Front. Med.*, vol. 12, pp. 1-7, 2025, doi: 10.3389/fmed.2025.1543434.
- [50] Y. Kataoka, T. Takemura, M. Sasajima, and N. Katoh, "Development and early feasibility of chatbots for educating patients with lung cancer and their caregivers in Japan: mixed methods study," *JMIR Cancer*, vol. 7, no. 1, e26911, 2021, doi: 10.2196/26911.
- [51] Y. You, C. H. Tsai, Y. Li, F. Ma, C. Heron, and X. Gui, "Beyond self-diagnosis: how a chatbot-based symptom checker should respond," *ACM Trans. Comput.-Hum. Interact.*, vol. 30, no. 4, pp. 1-44, 2023, doi: 10.1145/358995.
- [52] Z. Jahangir, Y. A. R. Shah, S. M. Qureshi, H. A. Qureshi, S. U. R. Shah, and J. S. Naguib, "From data to decisions: The AI revolution in diabetes care," *Int. J.*, vol. 10, no. 5, pp. 1162-1179, 2023.
- [53] P. K. Maraju, "Conversational AI for Personalized Financial Advice in the BFSI Sector," *International Journal of Innovations in Applied Sciences and Engineering*, vol. 8, no.2, pp. 156–177, Nov. 2022.
- [54] Sandeep Rangineni Latha Thamma reddy Sudheer Kumar Kothuru , Venkata Surendra Kumar, Anil Kumar Vadlamudi. Analysis on Data Engineering: Solving Data preparation tasks with ChatGPT to finish Data Preparation. *Journal of Emerging Technologies and Innovative Research*. 2023/12. (10)12, PP 11, <https://www.jetir.org/view?paper=JETIR2312580>.
- [55] Sehrawat, S. K. (2024). Leveraging AI for early detection of chronic diseases through patient data integration. *AVE Trends in Intelligent Health Letters*, 1(3), 125-136.
- [56] Panyaram, S. (2024). Utilizing quantum computing to enhance artificial intelligence in healthcare for predictive analytics and personalized medicine. *FMDB Transactions on Sustainable Computing Systems*, 2(1), 22-31.